Relx’s (REL) Sell Rating Reiterated at UBS Group
UBS Group restated their sell rating on shares of Relx (LON:REL) in a research note released on Tuesday morning, ThisIsMoney.Co.Uk reports.
A number of other research analysts also recently weighed in on REL. Numis Securities reissued a hold rating and issued a GBX 1,585 ($20.71) price objective on shares of Relx in a research note on Thursday, February 21st. Liberum Capital reissued a buy rating on shares of Relx in a research note on Thursday, March 7th. JPMorgan Chase & Co. reissued an overweight rating on shares of Relx in a research note on Monday, April 8th. Deutsche Bank reissued a hold rating on shares of Relx in a research note on Friday, February 22nd. Finally, Kepler Capital Markets cut their price objective on Relx from GBX 1,900 ($24.83) to GBX 1,780 ($23.26) and set a buy rating on the stock in a research note on Thursday, January 10th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of GBX 1,788.08 ($23.36).
Shares of REL stock opened at GBX 1,728.50 ($22.59) on Tuesday. The company has a current ratio of 0.44, a quick ratio of 0.36 and a debt-to-equity ratio of 270.50. Relx has a twelve month low of GBX 1,466.50 ($19.16) and a twelve month high of GBX 1,781.50 ($23.28). The company has a market capitalization of $33.82 billion and a P/E ratio of 24.21.
In related news, insider Erik Engstrom sold 36,334 shares of the firm’s stock in a transaction that occurred on Friday, February 22nd. The stock was sold at an average price of GBX 1,770 ($23.13), for a total value of £643,111.80 ($840,339.47).
RELX PLC provides information based-analytics and decision tools for professional and business customers in the United States and internationally. It operates through four segments: Scientific, Technical & Medical; Risk & Business Analytics; and Exhibitions. The Scientific, Technical & Medical segment provides information and analytics to institutions and professionals that enables progress in science, advance healthcare, and performance improvement.
Read More: New Google Finance Tool and Screening Stocks
Receive News & Ratings for Relx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Relx and related companies with MarketBeat.com's FREE daily email newsletter.